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Mycoplasmal lipoproteinsCalpain (intracellular Ca2+-dependent protease) and calpastatin (calpain speciﬁc endogenous inhibitor) are
widely distributed in biological systems, and have been implicated in many cellular physiological and patholog-
ical processes. Calpastatin level is of central importance to the control of calpain activity.We demonstrated for the
ﬁrst time that calpastatin is overexpressed in mycoplasma-contaminated cultured cells (SH-SY5Y cells that are
infected by a strain ofMycoplasma hyorhinis (NDMh)). We have found that the calpastatin-upregulating activity
resides in the mycoplasmal membrane lipoproteins, and is associated with NF-κB activation. Calpain-promoted
proteolysis is attenuated in the NDMh lipoprotein-treated cells. Here we show that the NDMh lipoproteins pro-
moted an increase in calpastatin in SH-SY5Y cells via the TLR2/TAK1/NF-κB pathway. The syntheticmycoplasmal
lipopeptide MALP-2 and the bacterial lipopeptide PAM3CSK4 (TLR2 agonists) also promoted calpastatin
upregulation. LPS (TLR4 agonist) activated NF-κB without calpastatin increase in the cell. In contrast, lipoteichoic
acid (TLR2 agonist) upregulated calpastatin not via NF-κB activation, but via the MEK1/ELK1 pathway. Zymosan
and peptidoglycan, TLR2 agonists that lack lipids, did not induce calpastatin upregulation. Cell treatment with a
calpastatin-upregulating agonist (lipoteichoic acid) led to the attenuation of Ca2+-promoted calpain activity,
whereas agonists that do not upregulate calpastatin (LPS, Zymosan)were ineffective. Overall, the results indicate
that in these non-immune cells, calpastatin is upregulated by TLR2-agonists containing lipids,withmore than one
downstream pathway involved. Such agonists may be useful for studying mechanisms and factors involved in
calpastatin regulation. In addition, suitable TLR2 agonists may be of interest in devising treatments for patholog-
ical processes involving excessive calpain activation.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The intracellular Ca2+-dependent protease calpain is widely distrib-
uted in biological systems, with two major calpain isozymes known,
μ-calpain and m-calpain, activated by micromolar and millimolar
Ca2+, respectively. Activated calpain causes a limited degradation of a
variety of proteins, including cytoskeletal proteins, membrane integral
proteins, certain enzymes, components involved in cell adhesion and
in signaling pathways. Calpain has been implicated in various cellular
physiological and pathological processes such as cellmotility, cell differ-
entiation, myoblast fusion, signal transduction pathways, neurotoxicity
and neurodegenerative diseases, apoptosis and necrosis [1].
Calpastatin, the intracellular speciﬁc endogenous inhibitor of calpain,
is also ubiquitous. The ratio of calpastatin to calpain varies among cells,






rights reserved.importance to the control of calpain activity within the cell. High levels
of calpastatin modulate calpain activity in physiological processes and
protect the cell from calpain overactivation in pathological conditions [1].
Endogenous calpastatin levels vary among cells, tissues, during cell
differentiation, and during development [2–5]. Limited information is
available on themechanisms and factors involved in calpastatin regula-
tion.We have shown for the ﬁrst time that calpastatin is upregulated in
Mycoplasma hyorhinis-contaminated cultured neuroblastoma SH-SY5Y
cells [6]. Mycoplasmas are widely distributed in nature and are distin-
guished from ordinary bacteria by their small size and minute genome.
They have limited biosynthetic abilities and most are extracellular par-
asites, adhering to the host cell membrane [7]. Mycoplasmas frequently
contaminate tissue culture cells, and contamination leads to a variety of
alterations in the cells, including alterations in gene expression, cell
membrane composition and changes in signal transduction [8]. Myco-
plasma is the ﬁrst naturally occurring biological system shown to
upregulate mammalian cell calpastatin [6,8].
We have found that lipoproteins (LPP) extracted from M. hyorhinis
are responsible for the upregulation of calpastatin in SH-SY5Y cells, by
activating the transcription factor NF-κB [9]. LPP are abundant in the
cell membrane of mycoplasmas, and are known to be potent macro-
phage activators [7]. The mycoplasmal LPP stimulate the immune cells
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face of the immune cells, particularly TLR2 andTLR6 [10]. LPP also interact
with non-immune cells [11–13], with little information available on their
mode of interaction with the non-immune cell membrane, on the path-
ways involved and on cellular proteins affected by them. Here we show
that M. hyorhinis LPP promote the increase in calpastatin in SH-SY5Y
cells via TLR2. The synthetic mycoplasmal macrophage activating
lipopeptide 2 (MALP-2) (a TLR2/TLR6 agonist) and the synthetic bacterial
lipopeptide Pam3-Cys-Ser-Lys4 (PAM3CSK4) (a TLR2/TLR1 agonist)
[14,15], also promote calpastatin upregulation. We compared the effects
of the mycoplasmal LPP and the synthetic lipopeptides to effects of
other TLR agonists. LPS, a lipopolysaccharide TLR4 agonist [16], activated
NF-κΒ but did not induce increase in the neuronal cell calpastatin. In con-
trast, lipoteichoic acid (LTA), a TLR2 agonist [17] induced an increase in
calpastatin levels, without activation of NF-κB. Zymosan and peptidogly-
can, TLR2/TLR6 agonists that lack lipids [18,19], did not induce an increase
in the calpastatin levels. Cell treatment with calpastatin-upregulating ag-
onists led to attenuation of Ca2+-promoted calpain activity, whereas ag-
onists that did not upregulate calpastatin were ineffective. Overall, the
results show that in these non-immune cells, calpastatin is upregulated
by TLR2-agonists containing lipids, with more than one down-stream
pathway involved, depending on the nature of the TLR2 agonist. Suitable
TLR2 agonists may be used as calpain inhibitors.
2. Materials and methods
2.1. SH-SY5Y cell culture, and cell treatment with TLR agonists, with
Ca2+/ionomycin, and with TLR pathways inhibitors
Mycoplasma-free SH-SY5Y cells were grown in RPMI-1640
supplemented with 2 mM L-glutamine, 10% FCS, and with added
40 ng ml−1 gentamycin in 25 cm2 plastic culture ﬂasks. For treatment
with the various TLR agonists and inhibitors, SH-SY5Y cells were placed
in petri dishes.
The TLR agonists used were: LPP, isolated from M. hyorhinis
(NDMh), as previously described [9], and added at a ﬁnal concentra-
tion of 0.3 μg/ml of medium; macrophage-activating lipopeptide
MALP-2 (ALX-162-027, Alexis Biochemicals, San Diego, CA, USA)
(stock solution of 10 μg/ml) was added at a ﬁnal concentration of
40 ng/ml; PAM3CSK4 (InvivoGen, San Diego, CA, USA) (stock solution
of 1 mg/ml) was added at a ﬁnal concentration of 10 μg/ml; Escherichia
coli lipopolysaccharide LPS (0111:B4) (L2654, Sigma-Aldrich, St. Louis,
USA) (stock solution of 1 mg/ml) was added at ﬁnal concentrations of
50 ng/ml−1 μg/ml; lipopolysaccharide LPS (E. coli K12, D31m4(Re))
(List Biological Laboratories Inc., California, USA) (stock solution of
1 mg/ml) was added at a ﬁnal concentration of 100 ng/ml; Lipoteichoic
acid (LTA), puriﬁed from Staphylococcus aureus, (InvivoGen, San Diego,
CA, USA) (stock solution of 300 μg/ml) was added at a ﬁnal concentra-
tion of 100 ng/ml; Zymosan A, polysaccharide from Saccharomyces
cerevisiae (Z4250, Sigma-Aldrich) (stock solution of 2.5 mg/ml) was
added at a ﬁnal concentration of 25 μg/ml; Peptidoglycan from Bacillus
subtilis (PGN) (69554, Sigma-Aldrich) (stock solution of 10 mg/ml)was
added at a ﬁnal concentration of 6 μg/ml.
The inhibitors used were: Anti TLR-2 antibody (αTLR) (N-17
(Sc-8689, Santa Cruz Biotechnology, Santa Cruz, CA, USA)) (stock solu-
tion of 200 μg/ml) was added at a ﬁnal concentration of 6.6 μg/ml; the
TAK1 inhibitor (5Z)-7-Oxozeaenol (499610, Calbiochem) (stock solution
of 300 μM)was added at a ﬁnal concentration of 300 nM; the IKK inhib-
itor PS1145 (Sc-301621, Santa Cruz Biotechnology, Santa Cruz, CA, USA)
(stock solution of 10 mM) was added at a ﬁnal concentration of 10 μM;
the MEK 1/2 selective inhibitor PD98059 (513000, Calbiochem, MERCK,
Darmstadt, Germany) (stock solution of 10 mM) was added at a ﬁnal
concentration of 10 μM; The synthetic cell penetrating peptide TAT-
DEF-ELK1 (TDE) that inhibits ERK-induced ELK1 phosphorylation [20]
(a generous gift from J. Caboche, Université Pierre et Marie Curie, Paris,
France, patents EP 05 290 363 and WO 2006/087242) (stock solutionof 1 mM)was added at a ﬁnal concentration of 10 μM; the p38MAPK in-
hibitor SB203580 (5633, Cell Signaling Technology, MA, USA) (stock so-
lution of 30 mM) was added at a ﬁnal concentration of 1 μM.
The inhibitorswere added to the cell cultures 1 h before adding the
TLR agonists. Cell cultureswere continued for 72 h in the presence and
absence of the agonists and inhibitors.
To study the effects of Ca2+ on the control and TLR agonists-treated
cells, CaCl2 (5 mM stock solution) and ionomycin (Calbiochem, La Jolla,
CA, USA), (0.5 mM stock solution in DMSO) were added to the cell cul-
tures at ﬁnal concentrations of 0.5 mM and 0.5 μM, respectively, 48 h
after the addition of the TLR agonists, and cultures continued for 24 h.
2.2. Preparation of cell extracts
The cultured cells were washed in PBS, lysed and analyzed by im-
munoblotting (see below). Total SH-SY5Y cell lysates were prepared
using 20 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100,
2.5 mM EDTA, 2.5 mM EGTA and 1: 200 protease inhibitors cocktail
set III (Calbiochem, MERCK, Darmstadt, Germany). Lysates were kept
on ice for 30 min and centrifuged. The protein concentration in the su-
pernatants was determined, and aliquots of supernatants were mixed
with Laemmli sample buffer for SDS–PAGE, as described previously [21].
For nuclear extracts, SH-SY5Y cell lysates were prepared using
20 mM Tris–HCl, pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 2.5 mM
EDTA, 2.5 mM EGTA and 1: 200 protease inhibitors cocktail set III
(Calbiochem). Lysates were kept on ice for 20 min and centrifuged
10 min at 1000 g at 4 °C. Protein concentration was determined in
the supernatants (cytosol fraction). The pellets (nuclear fraction)
were suspended in a buffer containing 20 mM Tris–HCl, pH 7.4,
150 mM NaCl, 1% Triton X-100, 2.5 mM EDTA, 2.5 mM EGTA and 1:
200 protease inhibitors cocktail set III (Calbiochem). The nuclear frac-
tions were mixed with Laemmli sample buffer and sonicated 3 times
for 10 sec. All the samples were boiled for 3 min.
2.3. SDS–PAGE and immunoblotting analyses
SDS–PAGEwas carried out according to standardprocedures, as previ-
ously described [21] (using 10% acrylamide gel for calpastatin, NF-κB p65,
NF-κB p50, and 6.5% acrylamide gel for fodrin). Samples containing
20–40 μg of SH-SY5Y cell proteins were electrophoresed and then trans-
ferred to nitrocellulose membranes (Schleicher & Schuell, Maidstone,
UK). Immunoblotting was carried out as described previously [21],
using polyclonal anti-calpastatin antibody (H300: Sc-7561, Santa Cruz
Biotechnology, Santa Cruz, CA) (1:500); polyclonal anti-NF-κB p65 anti-
body (Sc-109, Santa Cruz Biotechnology) (1:500); polyclonal anti-NF-κB
p105/p50 antibody (1559-1, Epitomics Inc. CA, USA) (1:500);monoclonal
anti-non-erythroid spectrin (anti-fodrin) antibody (Chemicon Inter-
national, Temecula, CA, USA) (1:1000). The appropriate peroxidase-
conjugated secondary antibodies were used, and detection of bands
carried out with ECL (Pierce), as previously described [21]. Membranes
were reprobed with monoclonal anti-β tubulin antibody (T6199, Sigma-
Aldrich) (1:80,000) for the estimation of loading of cytoplasmic proteins,
and with either monoclonal anti-lamin A antibody (636: Sc-7292, Santa
Cruz Biotechnology) (1:1000), or polyclonal anti-B23 antibody (Santa
Cruz Biotechnology) (1:1000), or polyclonal anti-histone 3 antibody (His-
tone H3 (FL-136): Sc-10809, Santa Cruz) (1:000) for the estimation of
loading of nuclear proteins. Bands were quantiﬁed by densitometry.
2.4. Statistical analysis
Data are expressed as mean ± SEM. For the comparison of means
of two groups, t-test for independent samples was performed; when
control was considered as 100%, one sample t-test was performed
(where the test value = 100). All comparisons were two tailed;
p b 0.05 was considered as signiﬁcant. Data was analyzed with SPSS
17.0 (SPSS, Chicago, IL, USA).
Fig. 1. Inhibition of LPP-induced calpastatin upregulation in SH-SY5Y cells. Cultured cells were pretreated for 1 h with inhibitors, and cultures continued for 72 h in the presence of
lipoproteins (0.3 μg/ml). Calpastatin levels were determined by western blotting, as described in Materials and methods. Tubulin was used for the estimation of loading; % of control
denotes the calpastatin levels. (A) Cells pretreated with anti-TLR2 antibody (6.6 μg/ml). Graph represents means ± S.E.M. (N = 5) ***P b 0.001 versus control cells (considered
100%); ##P b 0.01 versus LPP-treated cells. (B) Cells pretreated with (5Z)-7-Oxozeaenol (300 nM). Graph represents means ± S.E.M. (N = 4) **P b 0.01 versus control cells (con-
sidered 100%); ##P b 0.01 versus LPP-treated cells. (C) Cells pretreated with PS1145 (10 μM). Graph represents means ± S.E.M. (N = 3; for PS1145 alone, average of two exper-
iments). **P b 0.01 versus control cells (considered 100%); ##P b 0.01 versus LPP-treated cells. C, control; LPP, lipoproteins; αTLR, anti-TLR2 antibody; OZ, (5Z)-7-Oxozeaenol; PS,
PS1145; Clps, calpastatin; Tubl, tubulin.
2371T. Vaisid, N.S. Kosower / Biochimica et Biophysica Acta 1833 (2013) 2369–23773. Results
3.1. Mycoplasmal LPP upregulate calpastatin via TLR2, through
TAK-1/IKK pathway
We have previously shown that LPP isolated from NDMh promote
the activation of NF-κB and upregulate calpastatin in SH-SY5Y cells;Fig. 2. Calpastatin is upregulated in SH-SY5Y cells treated with the lipopeptides MALP-2 an
PAM3CSK4. Calpastatin levels were determined by western blotting, as described in Material
calpastatin levels. (A) Cells treated with MALP-2 (40 ng/ml). Graph represents means ± S
PAM3CSK4 (10 μg/ml). Graph represents means ± S.E.M. (N = 3) *P b 0.05 versus controlthe IKK inhibitor PS1145 inhibits both [9]. To further probe the path-
way involved, we examined whether in these cells TLR2 is involved
and whether TAK1 is activated by NDMh-derived LPP. SH-SY5Y cells
were cultured in the presence and absence of anti-TLR2 antibody,
the TAK1 selective inhibitor (5Z)-7-Oxozeaenol [22] and the IKK in-
hibitor PS1145 [23] for 1 h. LPP was then added, and cultures contin-
ued for 72 h. Cells were then processed and analyzed for calpastatin,d PAM3CSK4. Cells were cultured for 72 h in the absence and presence of MALP-2 and
s and methods. Tubulin was used for the estimation of loading; % of control denotes the
.E.M. (N = 4) *P b 0.05 versus control cells (considered 100%). (B) Cells treated with
cells (considered 100%). C, control; PAM, PAM3CSK4; Clps, calpastatin; Tubl, tubulin.
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duced a signiﬁcant increase in cellular calpastatin. TLR2 antibody
and OZ inhibited the LPP-induced increase in calpastatin, similar to
the effect of PS-1145 (Fig. 1A, B, C). The results indicate that the my-
coplasmal LPP bind to TLR2 in these cells and upregulate calpastatin
via the activation of TAK1, and IKK.3.2. MALP-2 and PAM3CSK4 upregulate calpastatin
The lipopeptide MALP-2, originally isolated fromM. fermentans and
subsequently synthesized, has been widely used as potent inducer of
pro-inﬂammatory cytokines in innate immune cells, and also affects
other cells [14,24]. PAM3CSK4 is a synthetic lipopeptide that mimics
bacterial lipoproteins and shown to stimulate macrophages and certain
epithelial cells to release cytokines [15]. SH-SY5Y cells were cultured in
the presence and absence of MALP-2 and PAM3CSK4 for 72 h. Cells
were then processed and calpastatin levels determined. MALP-2 in-
duced an increase in cellular calpastatin. Similarly, PAM3CSK4 also pro-
moted an increase in cellular calpastatin (Fig. 2A, B). The results indicateFig. 3. LPS activates NF-κB, but does not upregulate calpastatin in SH-SY5Y cells. (A) Cells tre
levels, using tubulin for the estimation of loading. Graph represents means of 2–4 experime
the calpastatin levels versus the control (considered 100%). (B) NF-κB in the cell nuclei. Cell
alyzed for nuclear levels of p65 and p50 subunits, using the lamin A band for the estimati
untreated cells (considered 100%). (C)-(G) Cells pretreated with inhibitors, then LPS (100
Lamin A, B23, or Histon 3 (H3) were used for the estimation of loading. (C) Cells pretr
**P b 0.01 versus control cells (considered 100%); ##P b 0.01 versus LPS-treated cells. (D
*P b 0.05, **P b 0.01 versus control, untreated cells (considered 100%). (E) Cells pretreate
pretreated with SB203580 (1 μM). Graph represents means ± S.E.M. (N = 3); **P b 0
TAT-DEF-ELK1 (10 μM). Graph represents an average of two experiments. C, control; OZ, (5that small synthetic lipopeptides, known to be TLR2 agonists, have an
effect similar to that of the mycoplasmal LPP used here.
3.3. LPS activates NF-κB, but does not induce calpastatin upregulation
We probed the possibility that other bacterial ligands promote
upregulation of calpastatin in SH-SY5Y cells. LPS, a Gram-negative bac-
terial TLR4 agonist that activates immune system cells [16], was added
to cultured SH-SY5Y cells. As shown in Fig. 3A, the LPS serotype 0111:B4
did not promote any calpastatin increase, even at very high concentra-
tions. Similar results were obtained using another type of LPS (E. coli
K12, D31m4(Re)) (data not shown). LPS promoted NF-κB p65 and
p50 translocation to the nucleus (Fig. 3B). The TAK1 inhibitor
(5Z)-7-Oxozeaenol inhibited the LPS-induced translocation of p65 to
the nucleus (Fig. 3C). On the other hand, the IKK inhibitor PS1145 did
not have any effect on the translocation of NF-κB to the nucleus in the
LPS-treated cells (Fig. 3D), and did not have any effect on levels of
calpastatin in LPS-treated cells as compared to control, untreated cells
(data not shown). These results indicated that the activation of NF-κB
in the LPS-treated cells did not involve the classical TAK1-IKK-NF-κBated with LPS (50, 100, 1000 ng/ml) for 72 h. Cell extracts were analyzed for calpastatin
nts (N = 4 for LPS 50 ng/ml; N = 2 for LPS 100 and 1000 ng/ml); % of control denotes
s were cultured in the presence and absence of LPS (100 ng/ml); cell extracts were an-
on of loading. Graph represents means ± S.E.M. (N = 3–4) **P b 0.01 versus control,
ng/ml) added; cell nuclear extracts were analyzed for nuclear levels of p65 subunit.
eated with (5Z)-7-Oxozeaenol (300 μM). Graph represents means ± S.E.M. (N = 4)
) Cells pretreated with PS1145 (10 μM). Graph represents means ± S.E.M. (N = 3)
d with PD98059 (10 μM). Graph represents an average of two experiments. (F) Cells
.01 versus control, untreated cells (considered 100%). (G) Cells pretreated with
Z)-7-Oxozeaenol; PS, PS1145; PD, PD98059; SB, SB203580; TDE, TAT-DEF-ELK1.
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tion of NF-κB was ERK and/or p38 MAPK cascade-dependent [25,26],
we treated the cells with ERK and p38 MAPK pathways inhibitors. The
MEK1/2 inhibitor PD98059 inhibited the LPS-induced translocation of
p65 to the nucleus (Fig. 3E). Treatment of the cells with the p38
MAPK inhibitor SB203580 [26] andwith TDE, the inhibitor of ELK1 acti-
vation [20], did not alter the LPS-induced translocation of p65 (Fig. 3F,
G). These results suggested that in SH-SY5Y cells, LPS activated NF-κB
via a pathway involving TLR4-TAK1-MEK1/2-ERK, without affecting
ELK1 and that this pathway is different from the one responsible for
the regulation of calpastatin.
3.4. LTA increases calpastatin in SH-SY5Y cells, but does not activate NF-κB
Lipoteichoic acid (LTA) is a Gram-positive bacterial TLR2 agonist,
known to activate macrophages and neutrophils to synthesize and se-
cret pro-inﬂammatory cytokines [17,27,28]. The treatment of cultured
SH-SY5Y cells with LTA did not have any effect on the levels of nuclear
NF-κB p65 and p50 (Fig. 4A). LTA led to an increase in cellularFig. 4. Lipoteichoic acid (LTA) upregulates calpastatin, but does not activates NF-κB in SH-SY
were analyzed for levels of p65 and p50 subunits, using the B23 band for the estimation of
with LTA (100 ng/ml) for 24-72 h; cell extracts were analyzed for calpastatin levels. Graph
***P b 0.001 versus control, untreated cells (considered 100%). (C–E) cells pretreated for 1
LTA (100 ng/ml); cell extracts were analyzed for calpastatin levels. (C) Cells pretreated with
trol, untreated cells (considered 100%); ###P b 0.001 versus LTA-treated cells. (D) Cells pret
**P b 0.01, ***P b 0.001 versus control, untreated cells (considered 100%); (E) Cells pretrea
pretreated with TAT-DEF-ELK1. Graph represents means ± S.E.M. (N = 4); ***P b 0.001
cells. (G) Cells pretreated with SB203580 (1 μM). Graph represents an average of two
TAT-DEF-ELK1; Clps, calpastatin; Tubl, tubulin.calpastatin, with magnitude of response dependent on the duration of
LTA-treatment (Fig. 4B); the MEK1 inhibitor PD98059 inhibited the
LTA-induced increase in calpastatin (Fig. 4C), whereas the TAK1 inhibi-
tor (5Z)-7-Oxozeaenol and the IKK inhibitor PS1145 did not (Fig. 4D, E).
The ELK1-phosphorylation inhibitor TDE [20] inhibited the LTA-induced
increase in calpastatin (Fig. 4F), whereas the p38 MAPK inhibitor
SB203580 did not inhibit the LTA effect (Fig. 4G). The results indicated
that LTA increased calpastatin via a pathway involving MEK1-ERK1/2
and the activation of the transcription factor ELK1.
3.5. Zymosan and PGN do not upregulate calpastatin in SH-SY5Y cells
Zymosan consists of polysaccharide complexes isolated from yeast
cell wall. It activates innate immunity cells and promotes the release
of cytokines and chemokines [18]. Zymosan did not induce any acti-
vation of NF-κB and did not upregulate calpastatin in the SH-SY5Y
cells (Fig. 5A, B). Similarly, PGN, a bacterial peptidoglycan TLR2 ago-
nist that also activates the innate immune system [19], did not
upregulate calpastatin in the treated cells (data not shown).5Y cells. (A) Cultured cells were treated with LTA (100 ng/ml) for 72 h; nuclear extracts
loading. Graph represents means ± S.E.M. (N = 2–3). (B) Cultured cells were treated
represents means ± S.E.M. (N = 3; for 24 h, average of two experiments). *P b 0.05,
h with vehicle and with inhibitors, and cultures continued for 72 h without and with
PD98059 (10 μM). Graph represents means ± S.E.M. (N = 3); ***P b 0.001 versus con-
reated with (5Z)-7-Oxozeaenol (300 μM). Graph represents means ± S.E.M. (N = 3);
ted with PS1145 (10 μM). Graph represents an average of two experiments. (F) Cells
versus control, untreated cells (considered 100%); ###P b 0.001 versus LTA-treated
experiments. C, control; PD, PD98059; OZ, (5Z)-7-Oxozeaenol; PS, PS1145; TDE,
Fig. 5. Zymosan does not activate NF-κB and does not upregulate calpastatin in
SH-SY5Y cells. Cells were cultured for 72 h in the absence and presence of zymosan
(25 μg/ml). Cell and nuclear lysates were analyzed, as described in Materials and
methods. (A) Nuclear NF-κB p65; cell nuclear extracts were analyzed for nuclear levels
of p65 subunit, using the B23 band for the estimation of loading. Graph represents an
average of two experiments. (B) Calpastatin levels. Graph represents means ± S.E.M.
(N = 4). C, control; Clps, calpastatin; Tubl, tubulin.
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in cells treated with LTA, but not in cells treated with LPS and Zymosan
We have previously shown that SH-SY5Y cells exposed to elevated
cellular Ca2+ exhibit enhanced fodrin degradation. Infection of the
cells by viable NDMh and treatment by NDMh-derived LPP protect
SH-SY5Y cultured cells from the Ca2+-promoted fodrin degradation
[6,9]. Fodrin is an endogenous cellular substrate of calpain, and servesFig. 6. Effects of TLR agonists on fodrin degradation in SH-SY5Y cells. Cells were cultured fo
(25 μg/ml); cell cultures were continued for additional 24 h in the absence and presence of C
by western blotting, as described in Materials and methods. (A) LTA-treated cells. Grap
***P b 0.001 versus control, untreated cells (considered 100%); ###P b 0.001 versus Ca2+/io
erage of two experiments. Ca, Ca2+/ionomycin.as a marker for calpain activity, with fodrin fragments of 145/150 kDa
indicative of calpain-induced degradation [1]. Fodrin degradation to
145/150 kDa fragments was enhanced in the Ca2+/ionophore-treated
clean cells. Fodrin degradation was signiﬁcantly inhibited in the
LTA-treated cells exposed to Ca2+, with some inhibition noted in
the LTA-treated control cells (Fig. 6A), whereas degradation was not
inhibited by treatment with LPS and zymosan (Fig. 6B)
4. Discussion
The main ﬁndings in this paper are that certain microbial TLR2
agonists induce elevation in mammalian cell calpastatin, and that
calpastatin upregulation is achieved by more than one signaling path-
way. Calpastatin is synthesized from a single gene that containsmultiple
promoters, generating several different transcripts; these are alterna-
tively spliced to multiple mRNAs, resulting in multiple protein isoforms
[1,29]. Certain promoter sequences act to stimulate and some others to
inhibit calpastatin transcription [29,30]. Transcription of calpastatin has
been shown to be promoted by β-adrenergic agonists and activation of
cAMP/PKA-dependent pathways [1,30], and by hypoxia [31], with no in-
formation on the pathways responsible for the calpastatin upregulation.
The ﬁnding that mycoplasma promoted an elevation of calpastatin
in the cultured SH-SY5Y cells, and that the mycoplasmal lipoproteins
were responsible for the calpastatin upregulation, enabled us to use
this system to probe pathways involved in calpastatin regulation.
The fact that antibody to TLR2 inhibited the NDMh LPP-induced
calpastatin upregulation in the SH-SY5Y cells shows that endogenous
TRL2 serves as a receptor for LPP not only in immune cells but also in
non-immune cells. In preliminary experiments we found that LPP iso-
lated from other mycoplasma species also upregulate cellular
calpastatin in SH-SY5H cells, as well as in other tissue culture cells, in-
dicating that the effect is not speciﬁc to one species of LPP or to one
type of mammalian cell (T. Vaisid, J. Kornspan, S. Rottem and N.S.
Kosower, unpublished observations).r 48 h in the absence and presence of LTA (100 ng/ml), LPS (100 ng/ml), and zymosan
a2+/ionomycin (0.5 mM and 0.5 μM, respectively). Fodrin in cell extracts was analyzed
h represents means ± S.E.M (N = 3; for LTA alone, average of two experiments);
nomycin-treated cells. (B) Cells treated with LPS and zymosan. Graph represents an av-
Fig. 7. Schematic representation of the signaling pathways activated by the TLR ago-
nists LPP, LPS and LTA, and calpastatin upregulation: The TLR2 agonist LPP activates
the transcription factor NF-κB and upregulates calpastatin; the TLR4 agonist LPS acti-
vates NF-κB, but has no effect on calpastatin levels; the TLR2 agonist LTA activates
the transcription factor ELK1 and upregulates calpastatin. For details, see text, para-
graphs 3.1, 3.3, and 3.4.
Table 1
Effects of TLR agonists on calpastatin upregulation in neuroblastoma SH-SY5Y cells. The
notations + and Ø denote increased and unaltered calpastatin levels, respectively.
Agonists Receptor Calpastatin
upregulation
Mycolplasmal lipoproteins (LPP) TLR2 +
Mycoplasma diacyl lipopeptide (MALP-2) TLR2/6 +
Bacterial triacyl lipopeptide (PAM) TLR2 +
Gram-negative lipopolysaccharide (LPS) TLR4 Ø




Bacterial peptidoglycans (PGN) TLR2 Ø
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cytokines in macrophages and promotes maturation and function of
dentritic cells [14]. MALP-2 action in the immune cells depends on its
binding to the TLR2 in cooperation with TLR6 [15]. MALP-2 has been
shown to also affect non-immune cells [24]. The synthetic triacylated
lipopeptide PAM3CSK4, that mimics the acylated amino terminus of
bacterial lipoproteins, is a potent activator of thepro-inﬂammatory tran-
scription factor NF-κB [32], and has been shown to activate monocytes,
macrophages, dendritic cells, and adipocytes via TLR2 (perhapswith the
participation of TLR1) [15,32]. The results presented here indicate that
diacylated and triacylated lipopeptides that are fragments of mycoplas-
mal and bacterial LPP sufﬁce to trigger calpastatin upregulation in
non-immune cells that express endogenous surface TLR2.
In order to identify other TLR agonists that may be active in
upregulating calpastatin in non-immune cells, we tested the Gram-
negative lipopolysaccharide LPS, that binds to TLR4 of innate
immune cells, and initiates the activation of a variety of pro-
inﬂammatory genes [16]. TLR4 is also expressed in non-immune
cells [33,34]. The fact that treatment of SH-SY5Y cells with LPS acti-
vated NF-κB but did not upregulate calpastatin indicates that TLR4 is
present, but is not involved in calpastatin upregulation in these cells.
Moreover, since the IKK inhibitor PS1145 did not inhibit the LPS-
induced NF-κB translocation to the nucleus, NF-κB appeared to be acti-
vated in the LPS-treated cells via pathway(s) not involving IκB. Trigger-
ing TLR4 is known to activate TAK1 [35]. The ﬁnding here that the TAK1
inhibitor (5Z)-7-Oxozeaenol inhibited the LPS-induced NF-κB nuclear
translocation, indicates that a TLR4-TAK1 pathway is involved in the ac-
tivation of NF-κB, but not in calpastatin upregulation in the SH-SY5Y
cells. The TAK1-MKK3/6-p38-NF-κB pathway [26] does not appear to
be involved in the NF-κB activation in these cells, since the p38 inhibitor
SB203580 did not inhibit the LPS-induced NF-κB nuclear translocation.
The ﬁnding that the MEK1/2 inhibitor PD98059 inhibited the NF-κB ac-
tivation in the LPS-treated cells supports the possibility that in the cells
studied here, LPS activates NF-κB via TL4-TAK1-MEK1/2-ERK1/2 path-
way. The fact that LPS-promoted NF-κB activation was not inhibited
by the ELK1 phosphorylation inhibitor TAT-DEF-ELK1 indicates that
ELK1 is not involved in the LPS effect. Overall, the results are consistent
with the notion that a distinct TAK1 triggering is required for the
NF-κB-promoted upregulation of calpastatin, a triggering that is not pro-
vided by LPS.
In contrast to the effects of LPS, treatment of SH-SY5Y cells by the
TLR2 agonist LTA leads to elevation of calpastatin levels but does not ap-
pear to act via pathways that lead to NF-κB activation. The ﬁnding that
the TAK1 inhibitor OZ and the IKK inhibitor PS1145 did not have an ef-
fect on the LTA-induced calpastatin upregulation indicates that LTAdoes
not act via the TAK1-IKK pathway. In addition, the fact that the p38 in-
hibitor SB203580 did not inhibit the LTA-promoted increase in
calpastatin indicates that TAK1-p38 pathway is also not involved in
the LTA effect. On the other hand, the fact that the MEK1 inhibitor
PD98068 prevented calpastatin upregulation suggests that LTA acts
through a pathway involving TLR2-the MAPKKK Tpl2-MEK1/2-ERK1/2
to activate a non NF-κB transcription factor, as observed in other sys-
tems [36]. TDE is shown here to inhibit the LTA-induced calpastatin
upregulation. TDE inhibits ELK1 phosphorylation and activation induced
by ERK without interfering with ERK activity toward other substrates
[20,37]. Overall, these results indicate that the transcription factor
ELK1 is involved in the LTA-effects observed here.
We have previously found that in cultured SH-SY5Y cell treated
with mycoplasmal LPP, the response to LPP is dependent on the dura-
tion of the treatment and that a treatment by mycoplasmal LPP for
several days results in high levels of calpastatin in the cells [9]. Simi-
larly, a treatment for 72 h of SH-SY5Y cells by LTA is shown here to
lead to highly signiﬁcant elevation of cellular calpastatin. It is of inter-
est to note that such effects are different from known effects of vari-
ous TLR ligands on immune cells, in which a signiﬁcant elevation of
cytokine production can be achieved within 24 h [15,17,25].A scheme summarizing the effects of the TLR ligands and path-
ways involved is shown in Fig. 7. The possible participation of addi-
tional transcription factors and associated proteins in calpastatin
upregulation remains to be investigated.
TLRs play an important role in the response of the innate immune
cells to microbial antigens and to the induction of adaptive immune re-
sponses [16,38]. Among the identiﬁed TLRs, TLR2 appears to express a
broad selectivity and recognizes a variety of structurally heterogenous
microbial compounds known as pathogen-associatedmolecular patterns
[39]. Our results demonstrate that some, but not all TLR2 ligands pro-
mote calpastatin upregulation in the non-immune cells studied here.
TLR2 ligands that contain lipids (mycoplasmal LPP, lipopeptides, and
LTA) upregulate calpastatin. In contrast, the non-lipid TLR2 agonists
polysaccharide Zymosan and peptidoglycan PGN do not inﬂuence the
cellular calpastatin levels in the SH-SY5Y cells. The results are summa-
rized in Table 1. The results indicate that the calpastatin upregulating ac-
tivity may be due to certain lipids-containing TLR2 agonists [39]. It is of
interest to note that nonlipidated MALP-2 failed to induce cytokine se-
cretion by macrophages under conditions in which MALP-2 was very ef-
ﬁcient in promoting cytokine secretion [40]. Additionalwork is necessary
to identify the lipid elements in the active agonists that are responsible
for calpastatin upregulation, and establish the structure of those agonists.
It should also be pointed out that calpastatinmay be differently regulated
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other TLRs agonists, increase calpastatin in bonemarrow-derivedmacro-
phages; the pathways involved have not been identiﬁed [41]. The overall
results indicate that calpastatin gene expression is cell type- and
stimulus-dependent.
In addition to providing information regarding pathways and factors
involved in calpastatin regulation, the results presented here are of inter-
est for studies on calpain roles in physiological andpathological processes.
Cellular calpastatin levels are elevated in vivo in Tg mice overexpressing
calpastatin, and in cultured cells by transfection with calpastatin gene-
containing vector. Calpastatin overexpressionhas been shown to interfere
with some cellular physiological processes, such as myoblast fusion, cell
growth [1,42,43], and to attenuate a variety of pathological processes
such as spinal cord injury [3], neuronal excitotoxic death [44], Aβ-
induced cell damage [45,46], endotoxemia-induced myocardial dysfunc-
tion [47], and Alzheimer's disease neuropathology [48]. We found that
Aβ/Ca2+ induced calpain-related toxicity in SH-SY5Y cells. In cells con-
taminated bymycoplasma and bymycoplasmal LPP, in which calpastatin
is elevated, the calpain-induced toxicity is inhibited [6,9,49]. As shown in
the present study, the fact that LTA inhibits Ca2+-promoted calpain
activity, whereas zymosan and LPS do not, substantiate the notion that
mycoplasma,mycoplasmal LPP and lipid-containing TLR2 agonists inhibit
cellular calpain activity via upregulation of calpastatin. As is the case with
themycoplasmal LPP [9], LTA appears to have an inhibitory effect on cells
not exposed to high Ca2+, indicating that LTA-promoted calpastatin is ef-
fective in inhibiting calpain under normal conditions, i.e., in the absence of
a challenge to the cell.
In conclusion, some lipid-containing TLR2 agonists (lipoproteins,
lipopeptides and lipoteichoic acid) upregulate calpastatin in non-
immune cells, acting via two (or more) pathways. Since the level of cel-
lular calpastatin is an important factor in the control of calpain activity,
such agonists may be useful in studying the regulation of cellular
calpastatin expression. In addition, suitable TLR2 agonists may be of in-
terest in devising treatments for some pathological processes involving
excessive calpain activation [50].Acknowledgements
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